Literature DB >> 22487068

Determination of factors predictive of outcome for patients undergoing a pancreaticoduodenectomy of pancreatic head ductal adenocarcinomas.

Gareth Eeson1, Nicolas Chang, Colleen E McGahan, Fareeza Khurshed, Andrzej K Buczkowski, Charles H Scudamore, Garth L Warnock, Stephen W Chung.   

Abstract

INTRODUCTION: A pancreaticoduodenectomy is the reference treatment for a resectable pancreatic head ductal adenocarcinoma. The probability of 5-year survival in patients undergoing such treatment is 5-25% and is associated with relatively high peri-operative morbidity and mortality. The objective of the present study was to evaluate risk factors predictive of outcome for patients undergoing a pancreaticoduodenectomy for a pancreatic adenocarcinoma.
METHODS: This retrospective analysis incorporated data from the Vancouver General Hospital and the British Columbia Cancer Agency (BCCA) from 1999-2007.
RESULTS: The 5-year survival of 100 patients was 12% with a median survival of 16.5 months. Ninety-day mortality was 7%. Predictors of 90-day mortality included age ≥ 80 years (P < 0.001) and an American Society of Anesthesiologists (ASA) score = 3 (P= 0.012) by univariate analysis and age ≥80 years (P < 0.001) by multivariate analysis. The identifiable predictive factor for poor 5-year survival was an ASA score = 3 (P= 0.043) whereas a Dindo-Clavien surgical complication grade ≥ 3 was associated with a worse outcome (P= 0.013). Referral to the BCCA was associated with a favourable 5-year survival (P= 0.001).
CONCLUSIONS: The present study identifies risk factors for patient selection to enhance survival benefit in this patient population.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22487068      PMCID: PMC3384850          DOI: 10.1111/j.1477-2574.2012.00448.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  22 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 2.  Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands.

Authors:  N Tjarda van Heek; Koert F D Kuhlmann; Rob J Scholten; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Huug Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 5.  The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality.

Authors:  Mary L Fennell; Irene Prabhu Das; Steven Clauser; Nicholas Petrelli; Andrew Salner
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

8.  Hospital volume and late survival after cancer surgery.

Authors:  John D Birkmeyer; Yating Sun; Sandra L Wong; Therese A Stukel
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

Review 9.  An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.

Authors:  Alexander Stojadinovic; Ari Brooks; Axel Hoos; David P Jaques; Kevin C Conlon; Murray F Brennan
Journal:  J Am Coll Surg       Date:  2003-06       Impact factor: 6.113

10.  Effect of centralization of pancreaticoduodenectomy on nationwide hospital mortality and length of stay.

Authors:  B Topal; S Van de Sande; S Fieuws; F Penninckx
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

View more
  7 in total

1.  Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Authors:  Ching-Wei D Tzeng; Matthew H G Katz; Jason B Fleming; Jeffrey E Lee; Peter W T Pisters; Holly M Holmes; Gauri R Varadhachary; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2013-10-16       Impact factor: 3.452

2.  A meta-analysis of the predictive accuracy of postoperative mortality using the American Society of Anesthesiologists' physical status classification system.

Authors:  Chieh Yang Koo; Joseph A Hyder; Jonathan P Wanderer; Matthias Eikermann; Satya Krishna Ramachandran
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

3.  Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma.

Authors:  Ryan K Schmocker; David J Vanness; Caprice C Greenberg; Jeff A Havlena; Noelle K LoConte; Jennifer M Weiss; Heather B Neuman; Glen Leverson; Maureen A Smith; Emily R Winslow
Journal:  HPB (Oxford)       Date:  2017-02-23       Impact factor: 3.647

4.  Clinical outcomes of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma depending on preservation or resection of pylorus.

Authors:  Yeon Jin Kim; Sang Hyun Shin; In Woong Han; Youngju Ryu; Naru Kim; Dong Wook Choi; Jin Seok Heo
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-08-31

5.  Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Samuel J Tingle; John A Moir; Steven A White
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

6.  Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer.

Authors:  M T Huggett; M Jermyn; A Gillams; R Illing; S Mosse; M Novelli; E Kent; S G Bown; T Hasan; B W Pogue; S P Pereira
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

7.  Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.

Authors:  Matthew T Huggett; Slavica Tudzarova; Ian Proctor; Marco Loddo; Margaret G Keane; Kai Stoeber; Gareth H Williams; Stephen P Pereira
Journal:  Oncotarget       Date:  2016-04-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.